These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia]. Ise M; Sakai C; Kumagai K Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227 [TBL] [Abstract][Full Text] [Related]
7. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Xu L; Hunter ZR; Yang G; Cao Y; Liu X; Manning R; Tripsas C; Chen J; Patterson CJ; Kluk M; Kanan S; Castillo J; Lindeman N; Treon SP Leukemia; 2014 Aug; 28(8):1698-704. PubMed ID: 24509637 [TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775 [TBL] [Abstract][Full Text] [Related]
9. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535 [TBL] [Abstract][Full Text] [Related]
12. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040 [TBL] [Abstract][Full Text] [Related]
13. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation. Minzenmayer AN; Miranda RN; Powell PR; Parekh PK J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928 [TBL] [Abstract][Full Text] [Related]
14. [Successful diagnosis of lymphoplasmacytic lymphoma with IgG paraprotein using MYD88 L265P mutation analysis]. Abe M; Saburi M; Itani K; Kohno K; Soga Y; Kondo Y; Kawano Y; Nakayama T Rinsho Ketsueki; 2018; 59(6):695-697. PubMed ID: 29973445 [TBL] [Abstract][Full Text] [Related]
15. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639 [TBL] [Abstract][Full Text] [Related]
16. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Jiménez C; Sebastián E; Chillón MC; Giraldo P; Mariano Hernández J; Escalante F; González-López TJ; Aguilera C; de Coca AG; Murillo I; Alcoceba M; Balanzategui A; Sarasquete ME; Corral R; Marín LA; Paiva B; Ocio EM; Gutiérrez NC; González M; San Miguel JF; García-Sanz R Leukemia; 2013 Aug; 27(8):1722-8. PubMed ID: 23446312 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114 [TBL] [Abstract][Full Text] [Related]